Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma - The ASCO Post
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Cancers | Free Full-Text | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study - ScienceDirect
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study | International Journal of Gynecologic Cancer
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Adding Olaparib to Bevacizumab Maintenance Improves Progression
A Phase 3 Trial of Bevacizumab in Ovarian Cancer | NEJM
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Bevacizumab in the Management of Epithelial Ovarian Cancer | touchONCOLOGY
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 | British Journal of
Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer | MedPage Today
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
Overall survival according to the addition of bevacizumab to first-line... | Download Scientific Diagram
Figure 3 from Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. | Semantic Scholar
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
